Celadon Pharmaceuticals (CEL)

Sector:

Alternative Investment Instruments

Index:

FTSE AIM All-Share

 117.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 172.50
  • 52 Week Low: 79.00
  • Currency: UK Pounds
  • Shares Issued: 64.21m
  • Volume: 0
  • Market Cap: £75.45m
  • RiskGrade: 111

Broker Views

Show broker recommendations:
Show broker actions:
Date Broker name New Price Old price target New price target Broker change
29-Sep-23 Canaccord Genuity Speculative Buy 122.50p 210.00p 235.00p Reiteration
05-Jun-23 Canaccord Genuity Speculative Buy 162.50p - 210.00p Reiteration
20-Apr-23 Canaccord Genuity Speculative Buy 162.00p - 210.00p Reiteration
30-May-22 Canaccord Genuity Speculative Buy 104.00p - 210.00p New Coverage

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Consensus broker estimates sourced from FactSet Research Systems Inc., who calculate consensus using only those estimates changed or actively validated within the last 75 days.

 

CEL Market Data

Currency UK Pounds
Share Price 117.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 172.50
52 Week Low 79.00
Volume 0
Shares Issued 64.21m
Market Cap £75.45m
RiskGrade 111

CEL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Income Not Available
Growth
Market averageMarket averageMarket averageMarket averageMarket average
12.5% below the sector average12.5% below the sector average12.5% below the sector average12.5% below the sector average12.5% below the sector average

CEL Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

CEL Key Personnel

CEO James Short
CFO Jonathan Turner

Top of Page